Announcement from Biorasi, LLC: Melissa Alesse Appointed President as Chris O'Brien Steps into Board of Directors Role

ECONOMY 18.03.2026

MIAMI, FL / ACCESS Newswire / March 18, 2026 / Biorasi, a leading global contract research organization (CRO) specializing in delivering confident clinical trials for emerging biotech sponsors, has announced that Chris O'Brien will be transitioning from his role as Chief Executive Officer and that Melissa Alesse, current Chief Operating Officer, has been appointed as the President of Biorasi effective today. O'Brien will continue to support Biorasi as a member of its Board of Directors.

Text size:

"Leading Biorasi has been one of the most meaningful and fascinating chapters of my career," said O'Brien. "I am fully confident in Melissa's leadership, and I look forward to supporting the company as a member of the Biorasi Board."

The planned transition reflects Biorasi's commitment to continuity, stability, and industry leadership. Alesse has played a central role in shaping a new direction founded on collaborative control and operational excellence - strengthening the company's capabilities in delivering efficient, goal-focused programs for sponsors worldwide.

Alesse has also been instrumental in enhancing operational rigor across the organization, guiding teams through key transformations in delivery, quality, and customer experience.

"I am so honored to be stepping into this role and continue Biorasi's commitment to today's biotech and biopharma companies," said Alesse. "We will continue to build upon our 20+ years of meeting and exceeding sponsor study goals and driving speed to market for innovative drug development. I am also proud to be carrying on Chris's legacy as the new host of the Few & Far Between podcast."

Biorasi's Board, led by RLH Equity Partners, has strongly endorsed Alesse's new appointment and praised O'Brien's contributions to the company's growth and performance.

"We thank Chris for his outstanding leadership achievements at Biorasi, representing clinical trial efficiency, expert guidance, and true thought leadership," said Rob Rodin of RLH Equity Partners. "We look forward to seeing Melissa lead Biorasi's strategy, operations, and execution with a focus on efficiency, transparency, and predictable clinical trial delivery."

About Biorasi

Biorasi is a full-service clinical research organization (CRO) focused on helping emerging and mid-size biopharma companies successfully advance their clinical programs with confidence. With an emphasis on operational excellence and collaborative control, Biorasi delivers tailored clinical trial solutions designed to meet the unique needs of each drug development program. Contact Biorasi at [email protected] / (786) 388-0700.

SOURCE: Biorasi, LLC

View the original press release on ACCESS Newswire

O.Norris--AMWN

CMSD	0.04%	22.89	$
CMSC	-0.53%	22.83	$
BCC	-1.5%	71.84	$
RBGPF	0.12%	82.5	$
NGG	-3.46%	87.4	$
RIO	-2.37%	87.72	$
BCE	-1.01%	25.75	$
GSK	-2.59%	52.06	$
RYCEF	-1.08%	16.6	$
JRI	-1.11%	12.323	$
BP	1.7%	44.61	$
AZN	-1.52%	188.42	$
BTI	-4.23%	58.09	$
VOD	-2.64%	14.37	$
RELX	-1.27%	33.86	$

American Marconi Wireless News - Announcement from Biorasi, LLC: Melissa Alesse Appointed President as Chris O'Brien Steps into Board of Directors Role

Announcement from Biorasi, LLC: Melissa Alesse Appointed President as Chris O'Brien Steps into Board of Directors Role

Featured

Music popstar will.i.am meshes AI and 'micromobility'

US Fed Chair says 'no intention' of leaving board while probe ongoing

US stocks fall on latest oil price surge as Fed lifts inflation forecast

Iran targets Gulf energy sites after intel chief killed